Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Prevention of contamination in pharmaceutical industry

Joint Event on 2nd International Congress on Nosocomial and Healthcare Associated Infections & International Conference on Decontamination, Sterilization and Infection Control

Melissa Stefko

Wells Pharmacy Network, LLC, USA

Keynote: J Infect Dis Ther

DOI: 10.4172/2332-0877-C4-046

Abstract
Contamination of pharmaceutical products can cause catastrophic consequences in the pharmaceutical industry; from patient safety and patient access to drug shortages through business viability and sustainability. In the manufacturing of sterile pharmaceutical products, contamination prevention is a critical component for complying with state and federal regulations as well as protecting the safety of the public. In the wake of the meningitis outbreak of 2012, FDA and other regulatory agencies have heightened their approach and expectations on monitoring products for contamination. Although bioburden levels may be able to be controlled with suitable cleaning methods, preventing the occurrence is the best approach when assessing the risk of contamination for a facility and/or drug product. Cleanroom suites play a critical role in the creation of sterile pharmaceutical drug products. Although many methods of decontamination and sterilization have proven successful, prevention of the contamination is key to maintaining optimal microbial levels in an aseptic environment. This talk will discuss the top potential sources of contamination and how to effectively prevent them from contaminating product, the cleanroom suites and the significant impact an outbreak may have on the organization as a whole. Additionally, this talk with also evaluate the top potential sources of contamination in detail based on risk and the specific role they play in the pathway to contamination. Discussion topics include facility design, cleanroom behavior, gowning and cleaning requirements, etc.
Biography

Melissa Stefko is an experienced pharmaceutical and biotechnology professional with a background in Quality Assurance and Quality Control in aseptic sterile processing. Prior to joining Wells Pharmacy Network, She served as Head of Quality with a start-up 503B outsourcing pharmacy and gained a strong CGMP understanding through previous positions within pharmaceutical manufacturers. She is an active member of the American Society for Quality as a Certified Quality Auditor and is a member of Institute of Environmental Sciences and Technology, American Society for Microbiology, Parenteral Drug Association, and IACP. She holds Masters in Business Administration, Masters of Science in Biotechnology, and Regulatory Affairs Certificate.

E-mail: melissastefko@gmail.com

 

Top